Tiziana Life Sciences Ltd (NASDAQ:TLSA) Short Interest Update

Tiziana Life Sciences Ltd (NASDAQ:TLSA) was the target of a significant increase in short interest during the month of December. As of December 31st, there was short interest totalling 680,800 shares, an increase of 300.2% from the December 15th total of 170,100 shares. Currently, 1.0% of the shares of the stock are sold short. Based on an average daily volume of 348,300 shares, the days-to-cover ratio is currently 2.0 days.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Tiziana Life Sciences stock. Zhang Financial LLC raised its holdings in shares of Tiziana Life Sciences Ltd (NASDAQ:TLSA) by 24.2% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 69,387 shares of the company’s stock after acquiring an additional 13,500 shares during the period. Zhang Financial LLC owned about 0.07% of Tiziana Life Sciences worth $67,000 at the end of the most recent reporting period.

Tiziana Life Sciences Price Performance

TLSA stock traded down $0.09 during midday trading on Monday, reaching $0.75. The company had a trading volume of 395,438 shares, compared to its average volume of 486,784. The firm has a 50-day moving average price of $0.88 and a 200-day moving average price of $0.95. Tiziana Life Sciences has a 1 year low of $0.41 and a 1 year high of $1.74.

Tiziana Life Sciences Company Profile

Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases.